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Abstract
Background: The development of esophageal squamous cell carcinoma (ESCC) progresses a multistage process,
collectively known as precursor lesions, also called dysplasia (DYS) and carcinoma in situ (CIS), subsequent invasive
lesions and final metastasis. In this study, we are interested in investigating the expression of a variety of functional classes
of proteins in ESCC and its precursor lesions and characterizing the correlation of these proteins with ESCC malignant
progression.
Methods: Fas, FADD, caspase 8, CDC25B, fascin, CK14, CK4, annexin I, laminin-5γ2 and SPARC were analyzed using
immunohistochemistry on tissue microarray containing 205 ESCC and 173 adjacent precursor lesions as well as
corresponding normal mucosa. To confirm the immunohistochemical results, three proteins, fascin, CK14 and laminin-
5γ2, which were overexpressed in ESCC on tissue microarray, were detected in 12 ESCC cell lines by Western blot
assay.
Results: In ESCC and its precursor lesions, FADD, CDC25B, fascin, CK14, laminin-5γ2 and SPARC were overexpressed,
while Fas, caspase 8, CK4 and annexin I were underexpressed. The abnormalities of these proteins could be classified
into different groups in relation to the stages of ESCC development. They were "early" corresponding to mild and
moderate DYS with overexpression of fascin, FADD and CDC25B and underexpression of Fas, caspase 8, CK4 and
annexin I, "intermediate" to severe DYS and CIS with overexpression of FADD and CK14, and "late" to invasive lesions
(ESCC) and to advanced pTNM stage ESCC lesions with overexpression of CK14, laminin-5γ2 and SPARC.
Conclusion: Analyzing the protein expression patterns of Fas, FADD, caspase 8, CDC25B, fascin, CK14, CK4, annexin
I, laminin-5γ2 and SPARC would be valuable to develop rational strategies for early detection of lesions at risk in advance
as well as for prevention and treatment of ESCC.
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Background
Esophageal cancer is a common disease worldwide, espe-
cially in the north of China. Despite advances in therapy,
the overall 5-year survival rate of esophageal cancer still
remains less than 30% [1,2]. In contrast, 5-year survival
rate of early esophageal cancer is higher than 90% [3].
Thus, prevention and early detection remain the best hope
for a cure.
Squamous cell carcinoma is the most common histologi-
cal type of esophageal cancer in China. A multistage proc-
ess has been proposed for the evolution of esophageal
squamous cell carcinoma (ESCC), in which normal squa-
mous epithelia undergo a series of histological and
genetic progression towards noninvasive precursor
lesions, i.e., dysplasia (DYS) and carcinoma in situ (CIS),
then towards invasive cancer, and, finally towards deep
invasion and metastasis to lymph nodes and other organs.
Understanding the genetic mechanisms underlying the
progression is critical, because it would provide a clue for
early detection and chemoprevention strategies.
We and others have recently explored the global expres-
sion profiles of ESCC with three different gene expression
platforms (serial analysis of gene expression, oligonucle-
otide microarray, and cDNA microarray) [4-10], and have
identified a multitude of genes that were overexpressed or
underexpressed on transcriptional level in ESCC, com-
pared with normal epithelia/mucosa, including Fas,
FADD, caspase 8, CDC25B, fascin, CK14, CK4, annexin I,
laminin-5γ2 and SPARC, encompassing a variety of func-
tional classes. The results in these studies on the dysregu-
lation of most of the above genes such as CK14, CK4 and
SPARC were concordant [4-10].
Although cDNA microarray has been successfully used to
explore the gene expression in ESCC, it is difficult to be
used in the precursor lesions due to the difficulty to obtain
the dysplastic cells accurately. Only one study examined
the gene expression in precursor lesions and different
pTNM stages of ESCC using cDNA microarray, and
showed complex alterations of gene expression in each
stage of tumorigenesis [8]. At present, however, little has
been known about the alterations on protein level in dif-
ferent stages.
The method of tissue microarray (TMA), which could con-
firm the results of cDNA microarray on protein level, has
been popularly used for gene expression profiling in
many types of cancer including ESCC, but rarely in the
consecutive stages of carcinogenesis, especially in the pre-
cursor lesions. TMA is more accurate and convenient than
cDNA microarray for precursor lesions of ESCC. We have
constructed TMA comprised of tissues of a variety of
pTNM stages of ESCC, a variety of grades of precursor
lesions and normal epithelia/mucosa. In this study, we
examined the expression of the 10 protein markers men-
tioned above in ESCC and the precursor lesions compared
with normal epithelia/mucosa using TMA-based immu-
nohistochemistry. Based on the results of TMA-based
immunohistochemistry, we detected the expression of
three overexpressed proteins, fascin, CK14 and laminin-
5γ2 in 12 ESCC cell lines by Western blot assay to confirm
the immunohistochemical results.
Methods
Sample collection and TMA construction
205 esophageal cancer specimens used in this study were
originated from patients who had received esophagec-
tomy without radiotherapy and chemotherapy before
operations in Cancer Institute (Hospital), Peking Union
Medical College, Chinese Academy of Medical Sciences
from June, 2001 to June, 2002. Among these patients, 163
were male and 42 were female. The age of them ranged
from 33 to 83 years, with the mean of 58.3. 181 cancer tis-
sues combined with adjacent mucosa and distant normal
mucosa were cut immediately after surgery, fixed in 80%
ethanol and embedded in paraffin. The other 24 samples
were obtained from the archival paraffin blocks of the
Department of Pathology, which had been fixed in 10%
formalin. All the specimens were cut into 4 μm sections
and stained by conventional HE-staining method. All the
cases were diagnosed as squamous cell carcinoma by two
authors (SZ and LR). Among them, 48 were well differen-
tiated, 99 moderately differentiated and 58 poorly differ-
entiated. The cases were staged according to the UICC
1997 pTNM criteria. The 24 cases from the archives were
early stage lesions (I), selected consecutively, and the
other 181 cases were advanced stage ones (IIA 64, IIB 18,
III 90 and IV 9), selected randomly. 173 precursor lesions
in the adjacent mucosa were selected and classified as 22
mild DYS, 25 moderate DYS, 51 severe DYS, and 75 CIS.
The follow-up data were mainly gathered from clinical
notes or via phone call and mail. Disease-free survival
time was recorded by the number of months from the date
of surgery to the date when any of the following events
happened: recurrence, metastasis, or death of ESCC. We
had excluded the patients who were in stage I, who suf-
fered from severe post-operative complications, who died
of other tumors or other causes, and who had not been
definitely followed up. The patients were followed up for
a maximum period of 60 months and mean of 27
months. This study was approved by the review board of
Cancer Institute (Hospital), Peking Union Medical Col-
lege, Chinese Academy of Medical Sciences, and informed
consent was obtained from all patients.
For TMA construction, representative areas containing
morphologically representative ESCC, normal epithelia/BMC Cancer 2006, 6:296 http://www.biomedcentral.com/1471-2407/6/296
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mucosa and defined precursor lesions were circled on the
glass slides and used as a template. The TMA was con-
structed using a manual Tissue Arrayer (Beecher Instru-
ments, Silver Spring, MD) as previously described [11].
For each lesion, more than two 0.6-mm cores were
punched from the circled regions in the donor block ran-
domly (but not from specific areas) and arrayed on the
recipient block to ensure the representation and to avoid
missing information due to loss of tissue cores.
Immunohistochemistry and assessment
The standard streptavidin peroxidase (SP) method was
employed for immunostaining. Briefly, sections were cut
at 4 μm from the TMA blocks. After dewaxed in xylene and
rehydrated in alcohol and distilled water, antigen retrieval
was performed by micro-wave oven heating (10 minutes)
at middle power in 0.01 M sodium citrate buffer (pH 6.0)
or incubated with protease XXIV (Biogenex, San Ramon,
CA) (10 minutes) at room temperature (Table 1). Then,
sections were incubated with 3% hydrogen peroxide for
10 minutes to block endogenous peroxidase activity.
Nonspecific staining was blocked by 10% normal goat
serum (Vector Laboratories Inc, Burlingame, CA) for 10
minutes. The primary antibodies used, as well as their
respective dilutions, incubation conditions and sources,
were shown in Table 1. The bound antibody was detected
then with biotinylated anti-mouse/rabbit IgG(H+L) (Vec-
tor Laboratories Inc, Burlingame, CA) for 10 minutes and
horseradish peroxidase streptavidin (Beijing Zhongshan
Biotech, Beijing, China) for 10 minutes. 3,3'-diaminoben-
zidine (Maixin Biotech, Fuzhou, Fujian, China) was used
as the chromogen. Slides were lightly counterstained with
hematoxylin. In control experiments, the primary anti-
body was replaced by PBS. Internal positive controls were
available on the TMA itself, for example, basal cells in the
normal squamous cell epithelia expressed fascin and
CK14; normal sqaumous cell epithelia expressed Fas and
CK4; superficial layers of normal sqaumous cell epithelia
expressed caspase 8. For all immunohistochemical stains,
the pattern of staining in normal epithelia/mucosa was
considered to be the baseline for comparison with precur-
sor lesions and ESCC.
Because the staining intensity of Fas, FADD, caspase 8,
CDC25B, fascin, CK14, CK4 and annexin I was not uni-
form among different lesions, we scored these proteins
with the criteria combined intensity with the rate of posi-
tive cells. First, the intensity was graded as follows: 0, neg-
ative; 1, weak; 2, moderate; 3, strong. Second, the rate of
positive cells was graded: 0, <5%; 1, 5~25%; 2, 26~50%;
3, 51%~75%; 4, >75%. A final score was achieved by mul-
tiplication of the two scores above. Scores of 0~4 were
defined as "negative expression" (-); scores of 5~8 as
"weakly positive expression" (+), and scores of 9~12 as
"strongly positive expression" (++) [12].
For laminin-5γ2, the expression levels were graded on a
scale as follows: negative (-), no positive cells; weakly pos-
itive (+), cluster(s) of positive cells present, but account-
ing for less than 30%; strongly positive (++), cluster(s) of
positive cells more than 30% [13].
The staining of SPARC was graded in the stroma and can-
cer cells/normal epithelia separately. The extent of stain-
ing in tumor stroma/normal mucosa stroma was recorded
according to the criteria of Koukourakis MI et al. as fol-
lows: negative (-), no positive fibroblasts; weakly positive
(+), less than 50% of fibroblasts positive; strongly positive
(++), more than 50% of fibroblasts positive [14]. How-
ever, Koukourakis MI et al. only scored the stroma by
semi-quantitative method, but not the tumor cells/nor-
mal epithelia. We modified the criteria and also scored the
tumor cells/normal epithelia semi-quantitatively as fol-
lows: negative (-), no positive cells; weakly positive (+),
less than 30% cells positive; strongly positive (++), more
than 30% cells positive. We selected 30% as cut-off, like
the scoring criteria of laminin-5γ2, but not 50%, due to
the low expression level of SPARC in tumor cells.
Table 1: Antibodies
Antibody Clone Dilution &condition Pretreatment Source
Fas (C-20) 1:200 RT1 h MWO-CB Santa Cruz Bio, Santa Cruz, CA, USA
FADD 64A6 1:20 4°C overnight MWO-CB Novacastra, Newcastle upon Tyne, UK
Caspase 8 8CSP01 1:200 4°C overnight MWO-CB NeoMarkers, Fremont, CA, USA
CDC25B 1:50 RT1 h MWO-CB Cell Signaling, Beverly, MA, USA
Fascin 55K-2 1:50 RT1 h MWO-CB Dako Corp, Carpinteria, CA, USA
CK14 LL002 1:50 RT1 h MWO-CB NeoMarkers, Fremont, CA, USA
CK4 6B10 1:50 4°C overnight MWO-CB Novacastra, Newcastle upon Tyne, UK
Annexin 1 29 1:100 RT1 h MWO-CB BD Transduction Laboratories, Lexington, KY
Laminin-5γ2 D4B5 1:50 RT1 h Protease XXIV Chemicon, Temecula, CA, USA
SPARC 15G12 1:50 RT1 h MWO-CB Novacastra, Newcastle upon Tyne, UK
RT, room temperature
MWO-CB, microwave oven heating in citrate buffer.BMC Cancer 2006, 6:296 http://www.biomedcentral.com/1471-2407/6/296
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The immunohistochemically stained sections were
reviewed independently by two pathologists (SZ and LR).
As to the discordant cases, unanimous concordance was
reached after revising and discussing.
Cell culture
Human ESCC cell lines, EC9706, TE12, COLO-680N,
KYSE510, KYSE450, KYSE410, KYSE180, KYSE150,
KYSE140, KYSE70, KYSE30 and YES2 were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine
serum at 37°C under 5% CO2 and saturated moisture.
Western blot
Cultured cells were collected and dissolved in lysis buffer
containing 50 mM Tris-Cl (pH 8.0), 150 mM NaCl, 0.1%
SDS, 100 μg/ml PMSF, 2 μg/ml aprotinin, 2 μg/ml leupep-
tin, 1% NP-40 on ice for 30 minutes. After centrifugation,
the supernatant was collected for Western blot analysis.
Briefly, 50 μg cellular proteins were loaded onto 12%
SDS-PAGE gels. After electrophoresis, the proteins were
transferred to nitrocellulose membranes. The membranes
were blocked in 5% nonfat milk, and then incubated with
primary antibody, fascin (1:5000, diluted with 5% nonfat
milk), CK14 (1:500, diluted with 5% nonfat milk) or lam-
inin-5γ2 (1:500, diluted with PBS) for 3 hours at room
temperature. Sources of antibodies were shown in Table 1.
The membranes were washed with PBST (PBS with 0.1%
tween-20) and then incubated with horseradish peroxi-
dase-conjugated anti-mouse antibody at 1:4000 in 5%
nonfat milk. The signals were developed by an ECL kit
(Amersham, Arlington Height, IL) [15,16].
Trans-well cell migration assay
Cell migration was examined with a chemotaxis chamber
(Neuro Probe Inc. Gaithersburg, MD). Cells (1 × 104) in
50 μl culture medium were added to the upper chamber
of the device, and the lower chamber was filled with 30 μl
medium containing 5 μg/ml fibronectin (Sigma, St. Louis,
MO). A polycarbonate membrane with a pore size of 8 μm
was placed between the two chambers. The cells were
allowed to migrate at 37°C in a 5% CO2 humidified incu-
bator for 6 hours. Non-migrated cells on the upper surface
were carefully removed with a cotton swab. The filters
were then fixed in methanol for 10 minutes and stained
with Giemsa solution. Migration was quantified by count-
ing the migrated cells in 10 random high-powered fields
per filter. The experiments were repeated three times [15].
Statistical analysis
χ2 test performed with SPSS 10.0 for Windows (SPSS, Chi-
cago, IL, USA) was used to compare the expression of the
proteins among the consecutive stages of carcinogenesis,
including normal epithelia/mucosa, different grades of
precursor lesions and different pTNM stages of ESCC and
to assess the correlations between the expression of the
proteins in ESCC and clinicopathological characteristics,
including sex, age and differentiated grades. Survival anal-
ysis was carried out using Kaplan-Meier method with log-
rank test. P value of less than 0.05 was considered statisti-
cally significant.
Results
Protein expression in ESCC and the precursor lesions 
detected by immunohistochemistry
A summary for expression of the proteins in various histo-
logical categories of esophageal lesions was shown in
Table 2. In ESCC and the precursor lesions, fascin, FADD,
CDC25B, CK14, laminin-5γ2 and SPARC were overex-
pressed, while Fas, caspase 8, CK4 and annexin I were
underexpressed, compared with normal epithelia/
mucosa, which were consistent with previous studies on
mRNA level [4-10].
The representative immunohistochemical features of the
proteins were shown in Figure 1. The localization of posi-
tivity of the following proteins was interesting. Caspase 8
was strongly positive in superficial layers of normal epi-
thelia, but negative in all basal, superbasal cells of normal
epithelia, all precursor lesions and all ESCC. Fascin and
CK14 were positive only in basal cells of normal epithelia,
but diffusely positive in ESCC. Laminin-5γ2 was negative
in cytoplasm of normal epithelia and precursor lesions,
with basement membrane positive only, but it was
strongly positive in cytoplasm of cancer cells, especially
the cancer cells at the tumor-stroma interface in ESCC.
Moreover, positive expression of laminin-5γ2 could be
seen in the budding tumor cells of the microinvasive can-
cer. SPARC was negative in most normal mucosa and pre-
cursor lesions, but strongly positive in stromal fibroblasts
in most ESCC. High levels of cytoplasmic SPARC in cancer
cells could be seen in a few cases, and the immunoactivity
was detected mainly in the cancer cells localized at the
tumor-stroma interface, similar to the pattern of laminin-
5γ2. So it could be seen in most ESCC that SPARC was
prominently expressed by stromal fibroblasts in a back-
ground of negative cancer cell reactivity.
Most of the abnormalities of these proteins occurred at
mild and moderate DYS (overexpression of fascin, FADD,
CDC25B and underexpression of CK4, annexin I, Fas, cas-
pase 8), which were defined as "early" changes; some
occurred at severe DYS and CIS (overexpression of CK14
and FADD), defined as "intermediate" changes; some
occurred at the transition from severe DYS and CIS to
invasive lesions or at the transition from early stage ESCC
to late stage (overexpression of CK14, laminin-5γ2 and
SPARC), defined as "late" changes. Figure 2 demonstrated
our current model of abnormalities in the progression of
ESCC.BMC Cancer 2006, 6:296 http://www.biomedcentral.com/1471-2407/6/296
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In addition, we had detected the expression patterns of
mutant p53 protein in the TMA (see additional file 1).
Association between protein expression and 
clinicopathologic characteristics
The expression of SPARC in stromal fibroblasts was corre-
lated with sex, the expression of CK4 was correlated with
age and the expression of Fas, FADD, fascin, CK14, lam-
inin-5γ2 and SPARC in stromal fibroblasts was correlated
with the differentiated grades (Table 3).
Survival analysis
Survival analysis using the log-rank test showed that the
expression of FADD, laminin-5γ2 and SPARC was signifi-
Table 2: Summary of immunohistochemical abnormalities in different lesions
Precursor lesions* ESCC* P-value
Protein Normal Low# High## I IIA/IIB III/IV Pa Pb Pc Pd Pe Pf
- 22(11.8%) 28(65.1%) 71(62.8%) 14(77.8%) 42(55.3%) 56(57.7%)
Fas + 89(46.6%) 13(30.2%) 31(27.4%) 4(22.2%) 30(39.5%) 31(32.0%) <0.001 <0.001 0.583 0.295 0.184 0.355
++ 76(40.6%) 2(4.7%) 11(9.7%) 0 4(5.3%) 10(10.3%)
- 155(84.7%) 15(38.5%) 28(23.5%) 1(5.6%) 36(44.4%) 58(59.2%)
FADD + 25(13.7%) 20(51.3%) 56(47.1%) 11(61.1%) 40(49.4%) 28(28.6%) <0.001 <0.001 0.032 0.212 <0.001 0.013
++ 3(1.6%) 4(10.3%) 35(29.4%) 6(33.3%) 5(6.2%) 12(12.2%)
- 72(39.1%) 40(100%) 114(100%) 18(100%) 81(100%) 98(100%)
Caspase 8 + 76(41.3%) 0 0 0 0 0 ------ ------ ------ ------ ------ ------
++ 36(19.6%) 0 0 0 0 0
- 102(53.4%) 9(21.4%) 47(38.5%) 3(16.7%) 30(37.0%) 30(30.6%)
CDC25B + 76(39.8%) 26(61.9%) 45(36.9%) 5(27.8%) 43(53.1%) 59(60.2%) <0.001 0.001 0.018 0.021 <0.001 0.618
++ 13(6.8%) 7(16.7%) 30(24.6%) 10(55.6%) 8(9.9%) 9(9.2%)
- 152 ** (82.2%) 9(20.5%) 14(11.7%) 2(11.8%) 16(19.8%) 16(16.3%)
Fascin + 17(9.2%) 23(52.3%) 62(51.7%) 6(35.3%) 29(35.8%) 43(43.9%) <0.001 <0.001 0.272 0.402 0.701 0.203
++ 16(8.6%) 12(27.3%) 44(36.7%) 9(52.9%) 36(44.4%) 39(39.8%)
- 159**(86.9%) 30(78.9%) 65(59.0%) 13(68.4%) 29(35.8%) 33(34.0%)
CK14 + 16(8.7%) 5(13.2%) 29(26.4%) 3(15.8%) 12(14.8%) 24(24.7%) <0.001 0.436 0.035 0.612 0.019 0.241
++ 8(4.4%) 3(7.9%) 16(14.5%) 3(15.8%) 40(49.4%) 40(41.2%)
- 5(2.8%) 39(86.7%) 85(70.2%) 18(94.7%) 39(48.8%) 49(49.5%)
CK4 + 123(68.0%) 6(13.3%) 34(28.1%) 1(5.3%) 39(48.8%) 46(46.5%) <0.001 <0.001 0.020 0.079 0.001 0.832
++ 53(29.3%) 0 2(1.7%) 0 2(2.5%) 4(4.0%)
- 1(0.5%) 24(53.3%) 52(43.3%) 10(52.6%) 44(55.7%) 58(58.6%)
Annexin 1 + 48(26.0%) 16(35.6%) 46(38.3%) 6(31.6%) 30(38.0%) 30(30.3%) <0.001 <0.001 0.402 0.749 0.391 0.377
++ 136(73.5%) 5(11.1%) 22(18.3%) 3(15.8%) 5(6.3%) 11(11.1%)
- 181***(100%) 37(88.1%) 88(74.6%) 6(37.5%) 26(32.1%) 22(22.4%)
Laminin-5γ2 + 0 5(11.9%) 29(24.6%) 6(37.5%) 46(56.8%) 56(57.1%) ------ ------ 0.181 <0.001 0.227 0.142
++ 0 0 1(0.8%) 4(25%) 9(11.1%) 20(20.4%)
- 167(96.0%) 40(95.2%) 116(97.5%) 10(71.4%) 13(18.3%) 11(11.6%) <0.001 0.651 0.606 <0.001 <0.001 0.125
SPARC in stromal fibroblasts + 5(2.9%) 2(4.8%) 3(2.5%) 3(21.4%) 28(39.4%) 29(30.5%)
++ 2(1.1%) 0 0 1(7.1%) 30(42.3%) 55(57.9%)
- 174(100%) 42(95.5%) 117(96.7%) 18(100%) 76(93.8%) 90(91.8%)
SPARC in epithelial cells + 0 2(4.5%) 4(3.3%) 0 3(3.7%) 3(3.1%) ------ ------ ------ ------ ------ ------
++ 0 0 0 0 2(2.5%) 5(5.1%)
*Numbers of valid (informative) cases.
**Including cases of only basal cells positive labeling.
***Only basal membrane positive labeling in normal epithelia.
#Low: Mild & Moderate DYS; ##High: Severe DYS & CIS.
aEsophageal normal epithelia vs. ESCC. bEsophageal normal epithelia vs. Mild & Moderate DYS. cMild & Moderate DYS vs. Severe DYS & CIS. 
dSevere DYS & CIS vs. ESCC stage I. eESCC stage I vs. ESCC stage II. fESCC stage II vs. ESCC stage III & IV.BMC Cancer 2006, 6:296 http://www.biomedcentral.com/1471-2407/6/296
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Representative photographs of immunohistochemical features of the proteins in different lesions Figure 1
Representative photographs of immunohistochemical features of the proteins in different lesions. The proteins 
of interest are designated in rows, and the esophageal histological categories, normal esophageal mucosa (A) and various histo-
logical categories of lesions, i.e., mild DYS (B), severe DYS (C) and ESCC (D), are designated in columns. A1-D1, strongly 
positive expression of Fas in normal epithelia, but negative in mild, severe DYS and ESCC. A2-D2, negative expression of 
FADD in normal epithelia, but strongly positive in mild, severe DYS and ESCC. A3-D3, positive expression of fascin only in 
basal cells of normal epithelia, and strongly positive in mild, severe DYS and ESCC.A4-D4, positive expression of CK14 only in 
basal cells of normal epithelia, negative in mild DYS, but strongly positive in severe DYS and ESCC. A5-D5, negative expres-
sion of laminin-5γ2 in cytoplasm of normal epithelia and mild, severe DYS with positive expression only in basement mem-
brane, but strongly positive in cytoplasm of ESCC, especially at the tumor-stroma interface. Moreover, positive expression of 
laminin-5γ2 can be seen in the budding tumor cells of the microinvasive cancer (E). A6-D6, negative expression of SPARC in 
the epithelia and stroma in normal mucosa and mild, severe DYS, but prominent SPARC expression by stromal fibroblasts in a 
background of negative cancer cell reactivity in ESCC. Moreover, SPARC expression can be seen in the cytoplasm of the juxta-
stromal tumor cells in a few cases (F). (original magnification, ×200)
A1 B1 C1 D1
A2 B2 C2 D2
A3 B3 C3 D3
A4 B4 C4 D4
A5 B5 C5 D5
A6 B6 C6 D6
EFBMC Cancer 2006, 6:296 http://www.biomedcentral.com/1471-2407/6/296
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cantly correlated with disease-free survival (P = 0.0022, P
= 0.0380, and P = 0.0494, respectively) (Table 4 and Fig-
ure 3).
The expression of fascin, CK14 and laminin-5γ2 in ESCC 
cell lines
High expression of fascin was detected in almost all ESCC
cell lines utilized in our study, but not in cell line TE12.
Expression of CK14 was seen only in KYSE180. High
expression of laminin-5γ2 was detected in COLO-680N,
KYSE510, KYSE150, KYSE140, moderate in KYSE410,
KYSE180, KYSE70 and negative in others (Figure 4). We
analyzed the correlation of the expression of these three
proteins with the results of trans-well cell migration assay,
because cell-migration ability was closely associated with
the potential of invasion and metastasis [15]. According
An outline of our current understanding of protein expression changes in multistep progression of ESCC Figure 2
An outline of our current understanding of protein expression changes in multistep progression of ESCC. The 
"early" changes are those occurring at the transition from normal epithelia to mild and moderate DYS, the "intermediate" 
changes are those occurring at transition from mild and moderate DYS to severe DYS and CIS, and the "late" changes are 
those occurring at the transition from severe DYS and CIS to invasive lesions or at the transition from early stage ESCC to late 
stage. (1, normal epithelia/mucosa; 2 mild and moderate DYS; 3, severe DYS and CIS; 4, ESCC stage I; 5, ESCC stage IIA and 
IIB; 6, ESCC stage III and IV; ep, epithelium; lpm: lamina propria mucosa; mm: muscularis mucosa; sm: submucosa; mp, muscula-
ris propria; LN, lymph node.)
ep
lpm 
mm 
sm 
mp 
LN
|ĸ   1    ĺ||ĸ     2      ĺ||ĸ   3     ĺ||ĸ    4      ĺ||ĸ   5    ĺ||ĸ   6    ĺ|
             
Fas;Caspase8
CDC25B;
Fascin;CK4;
Annexin I 
                              CK14
FADD
CK14
     
Laminin-5Ȗ2
                                       
                                            SPARC 
“Early” changes  “Intermediate” changes    “Late” changes BMC Cancer 2006, 6:296 http://www.biomedcentral.com/1471-2407/6/296
Page 8 of 15
(page number not for citation purposes)
to the number of migrated cells in trans-well cell migra-
tion assay, the cell lines were classified into two groups.
Six cell lines, EC9706, KYSE450, KYSE180, COLO-680N,
KYSE410, KYSE510, which were classified as "strong"
migration group, had more migrated cells than the other
six cell lines, YES2, KYSE150, KYSE140, KYSE30, KYSE70,
TE12, classified as "weak" migration group. Among them,
EC9706 had the most migrated cells and TE12 had the
least migrated cells, which were defined as the "strongest"
and the "weakest", respectively. The correlation of the
expression of these three proteins with the results of trans-
well cell migration assay [15] and the correlation of the
expression of these three proteins with the differentiation
of the primary tumor of these cell lines [16,17] were
Table 3: Summary of correlation of immunohistochemical abnormalities with clinicopathologic characteristics in ESCC
Sex Age Differentiation
Protein Male Female P 60 <60 P well moderate poor P
- 9 22 0 5 35 9 1 65 64 0
Fas + 55 10 0.053 33 32 0.088 23 29 13 0.002
+ + 86 1 1 3 752
- 8 01 5 4 64 9 2 64 72 2
FADD + 59 20 0.278 40 39 0.781 21 33 25 0.043
+ + 1 9 41 3 1 00 1 5 8
- 4 91 4 3 82 5 1 72 91 7
CDC25B + 89 18 0.480 47 60 0.103 25 49 33 0.852
+ + 2 0 71 5 1 25 1 5 7
- 2 31 1 2 11 3 6 1 21 6
Fascin + 66 12 0.114 37 41 0.347 18 35 25 0.028
++ 68 16 41 43 23 46 15
- 5 91 6 3 83 7 6 2 74 2
CK14 + 35 4 0.241 20 19 0.977 11 21 7 <0.001
++ 64 19 41 42 31 44 8
- 9 01 6 5 05 6 1 75 33 6
CK4 + 66 20 0.242 49 37 0.018 27 39 20 0.056
+ + 42 06 321
- 92 0 49 63 22 51 39
Annexin 
1
+ 52 14 0.843 41 25 0.059 21 30 12 0.085
++ 15 4 9 10 5 12 5
- 3 91 5 2 62 8 1 11 62 7
Laminin-
5γ2
+ 90 18 0.191 59 49 0.425 32 57 19 <0.001
+ + 2 8 51 4 1 94 1 9 1 0
- 2 21 2 1 42 0 5 1 41 5
SPARC in 
stromal 
fibroblast
s
+ 48 12 0.031 26 34 0.079 11 27 22 0.004
++ 74 12 51 35 28 45 13
- 146 38 97 87 44 88 52
SPARC in 
epithelial 
cells
+51 0 . 3 9 7 15 0 . 1 0 8 132 0 . 8 6 6
+ + 70 25 223BMC Cancer 2006, 6:296 http://www.biomedcentral.com/1471-2407/6/296
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shown in Table 5. The cell line with negative expression of
fascin displayed the weakest migration in trans-well test,
and the cell lines with high and moderate expression of
laminin-5γ2 displayed stronger migration phenotypes
than those with negative expression of laminin-5γ2.
Discussion
Tumorigenesis is a multistep process that may involve
many genes. Analyzing alterations of gene expression pro-
files in different stages of neoplasia is a necessary step
towards establishing the diagnostic, prognostic, therapeu-
tic and preventive potential of each related gene. Accord-
ing to gene expression data previously established, we
further examined the immunohistochemical labeling of
10 protein markers using the TMA composed of different
pTNM stages of ESCC, different grades of precursor
lesions and normal mucosa.
Apoptosis related proteins (Fas, FADD, caspase 8)
Fas, a member of the tumor necrosis factor receptor super-
family, is a transmembrane protein which can bind its lig-
and (FasL) and induce apoptosis by triggering a cascade of
downstream effector caspases via FADD and caspase 8
[18]. Functional impairment of the apoptotic pathway is
associated with the development and progression of
malignancies by evading immune surveillance.
Downregulation of Fas has been demonstrated previously
in ESCC and its precursor lesions [19]. We further demon-
strated loss of Fas expression occurred at the phase as early
as mild and moderate DYS.
To our knowledge, detailed analysis of FADD protein
expression has not been performed in ESCC and its pre-
cursor lesions. In the present study, we demonstrated that
FADD was overexpressed in ESCC compared with normal
esophageal epithelia, consistent with the result on mRNA
level in cDNA microarray study [4]. Moreover, FADD was
overexpressed at the transition from normal epithelia to
mild and moderate DYS and at the transition from mild
and moderate DYS to severe DYS & CIS as an "early" and
"intermediate" event.
At present, there was little information about the expres-
sion of caspase 8 in ESCC and its precursor lesions. In this
study, we demonstrated that caspase 8 was strongly posi-
tive in the mature superficial layers of normal esophageal
epithelia, but negative in the basal and suprabasal layers
Table 4: Summary of correlation of immunohistochemical abnormalities with survival
Protein Expression Disease-free survival
5-year survival rate (%) P
-/+ 38.16
Fas ++ 36.36 0.7803
-/+ 41.88
FADD ++ 11.11 0.0022
-/+ 40.87
CDC25B ++ 38.82 0.7252
-/+ 40.56
Fascin ++ 38.14 0.6481
-/+ 33.81
CK14 ++ 44.41 0.4061
-/+ 33.54
CK4 ++ 44.44 0.2903
-/+ 40.74
Annexin 1 ++ 0 0.1617
-/+ 42.65
Laminin-5γ2 ++ 22.22 0.0380
-/+ 48.80
SPARC in stromal fibroblasts ++ 30.97 0.0494BMC Cancer 2006, 6:296 http://www.biomedcentral.com/1471-2407/6/296
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of normal esophageal epithelia, all precursor lesions and
all invasive cancers.
Cell cycle regulatory proteins (CDC25B)
Alterations in cell-cycle regulatory genes are commonly
found in human cancers. CDC25B is a dual specificity
phosphatase and can positively control the G2-M transi-
tion [20].
Overexpression of CDC25B protein in ESCC has been
reported previously [9,21]. In the present study, we fur-
ther investigated the expression of CDC25B in different
grades of DYS, CIS as well as in different pTNM stages of
ESCC. We demonstrated that CDC25B was overexpressed
in ESCC and the precursor lesions, and CDC25B overex-
pression was an "early" event, occurring at mild and mod-
erate DYS.
Cytoskeleton and related proteins (fascin, CK14 and CK4)
The cytoskeleton is a complex network of protein fila-
ments that extends throughout the cytoplasm of the
eukaryotic cells. It includes 3 types of protein filaments:
actin filaments, microtubules, and intermediate fila-
ments. Changes in cytoskeleton components or associ-
ated binding proteins may be implicated in the
progression and metastasis of tumors.
Fascin is a highly conserved actin-bundling protein. The
overexpression of fascin induces membrane protrusions
and cell motility. Immunoreactivity for fascin has been
reported in various malignancies [22,23]. Moreover,
upregulation of fascin has been considered as an "inter-
mediate" event in pancreatic carcinoma progression,
uncommon in early intraepithelial neoplasia lesions, but
substantially upregulated in advanced intraepithelial neo-
plasia lesions and nearly universal in invasive cancers
[24]. In the current study, we found that fascin overexpres-
sion occurred at mild and moderate DYS as an "early"
event, and was nearly universal in precursor lesions and
invasive cancers.
Yashimoto et al. demonstrated that all of the 33 cell lines
tested expressed fascin protein, and a fascin-overexpressed
cell line, KYSE170, decreased its motile and invasive prop-
erties after down-regulation of fascin expression by using
vector-based small interfering RNA [25]. In the present
study, high expression of fascin was detected in almost all
cell lines, but not in cell line TE12, which grew the slowest
and displayed the weakest migration [15]. These sug-
gested that fascin might play an important role in the pro-
gression of ESCC.
Cytokeratins are a family of intermediate filament pro-
teins typically found in epithelial cells. Based on the isoe-
lectric point and molecular weight, human cytokeratins
Representative survival curves of ESCC Figure 3
Representative survival curves of ESCC. Kaplan-Meier 
survival curves of patients with negative/weak or strong 
expression of FADD, laminin-5γ2 and SPARC.
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have been classified numerically as cytokeratins 1–20.
Carcinoma cells retain the ability to produce the cytok-
eratins of their normal progenitor cells and may also gain
the ability to develop new expression types.
Previous studies have demonstrated that CK14 protein
was expressed in squamous cell carcinoma regardless of
origin and degree of differentiation, and could be used as
a useful marker in diagnosis of squamous cell carcinoma
[26]. Takahashi H et al. demonstrated that CK14 selec-
tively labeled the basal cells of normal esophageal epithe-
lia and also labeled all DYS, all CIS and all ESCC. [27]. We
further found that dysregulation of CK14 might be an
"intermediate" and "late" event in ESCC progression,
uncommon in mild and moderate DYS, but substantially
upregulated in severe DYS and CIS and more universal in
relatively late stages of invasive cancers.
Expression of CK14 was only seen in cell line KYSE180. In
contrast, CK14 was expressed in most ESCC tissues. Simi-
lar phenomenon could be seen in oral cancer. CK14 was
overexpressed in most oral squamous cell carcinoma tis-
sue [28], but was lost or downregulated in oral squamous
cell carcinoma cell lines [29,30]. Moreover, it had been
demonstrated that the cytokeratin expression pattern
changed in normal esophageal epithelial cells during cul-
ture [31]. These suggested that the expression of CK14 in
ESCC cell lines might decrease during culture and passage.
CK4 is expressed during the development of stratified epi-
thelia from one-layered polar epithelia and continues to
be expressed in several adult nonepidermal stratified epi-
thelia including esophageal epithelia. Low levels of CK4
expression have been detected in squamous cell carci-
noma of the tongue, larynx and sinonasal tract [32,33]. In
nonkeratinizing squamous cell carcinoma of sinonasal
tract associated with a Schneiderian papilloma, CK4 was
expressed in the papilloma but not in the carcinoma from
the same cases [32]. So downregulation of CK4 might
occur during malignant transformation of these tumors.
Western blot of fascin, CK14 and laminin-5γ2 in 12 ESCC cell lines Figure 4
Western blot of fascin, CK14 and laminin-5γ2 in 12 ESCC cell lines. High expression of fascin was detected in almost 
all cell lines, but not in cell line TE12. Expression of CK14 was detected in cell line KYSE180. High expression of laminin-5γ2 
was detected in cell lines, COLO-680N, KYSE510, KYSE150 and KYSE140, and moderate expression was detected in 
KYSE410, KYSE180 and KYSE70.
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In the current study, CK4 was positively expressed in nor-
mal esophageal epithelia, but obviously decreased in
ESCC [33]. We found CK4 downregulation occurred at
mild and moderate DYS as an "early" event, which was
first reported.
Cell signaling protein (annexin I)
Annexin I is a member of the annexin family, which can
bind (annex) to cellular membranes in a calcium-depend-
ent manner. Recent data have shown that annexin I might
be an cell signaling protein and be implicated in the sign-
aling processes of inflammation, differentiation, apopto-
sis, coagulation, immune response and proliferation [34].
The role of annexin I in tumor biology is attracting grow-
ing interests. This is partly because characteristic distribu-
tion and expression of annexin I have been found in
different normal tissues, and dysregulation of annexin I
expression has been described in a variety of cancerous
and precancerous lesions [35-38]. Paweletz et al. demon-
strated that annexin I was downregulated in all ESCC,
compared with patient-matched normal epithelia, and
suggested that annexin I might be an essential component
for maintenance of the normal esophageal epithelial phe-
notype and its loss might be correlated with tumorigene-
sis. In addition, they analyzed 11 patient-matched cases
with different grades of lesions with the method of LCM
(laser capture microdissection) and Western blot, and
demonstrated that downregulation of annexin I was an
"early" event in the progression of ESCC, occurring either
at the junction between high-grade DYS and invasive phe-
notypes or at the low-grade to high-grade DYS transition
[37]. In the current study, dysregulation of annexin I
expression occurred at the transition from normal epithe-
lia to mild & moderate DYS, but not at the transition from
severe DYS & CIS to ESCC as a very "early" event. The dis-
cordance was perhaps due to the different methods and
the different cases utilized in the studies. Anyway, the dys-
regulation of annexin I occurred as a relatively "early"
change.
Extracellular matrix protein (laminin-5γ2) and 
matricellular protein (SPARC)
Laminins are a group of extracellular matrix proteins
localized at the basement membrane where they are
involved in cell adhesion, migration, proliferation, and
differentiation. Laminin-5 is a heterotrimeric glycosylated
protein that belongs to the laminin family and is formed
by α3β3γ2 chains, and the γ2 chain is unique to laminin-
5 [39]. Overexpression of the γ2 chain has been reported
in several malignancies, such as gastric, tongue, colon, cer-
vical cancer and melanoma. In addition, it has been dem-
onstrated to be implicated in cancer invasion and
metastasis [40-42].
In normal esophageal mucosa, we found that immunore-
activity for laminin-5γ2 was strong in basement mem-
brane, but negative in cytoplasm of epithelial cells. We
also found that immunoreactivity in basement membrane
was strong in specimens fixed in ethanol, but weak or neg-
ative in those fixed in formalin, which was similar to the
results of Aoki S et al. [43]. In our present study, only
11.9% of mild & moderate DYS and 25.4% of severe DYS
& CIS were positive (mainly weakly positive), with a ten-
dency of correlation between the grade of precursor
lesions and laminin-5γ2 immunoreactivity in cytoplasm,
consistent with previous studies in other tissues
[42,44,45]. As far as we know, this is the first report inves-
tigating the laminin-5γ2 chain staining pattern in esopha-
geal preinvasive lesions. In ESCC, strong expression was
seen in cytoplasm of cancer cells in most cases, especially
at the tumor-stroma interface. So the dysregulation of
laminin-5γ2 chain predominantly occurred at the transi-
tion of preinvasive lesions to ESCC as a "late" event.
Table 5: The correlation of the expression of fascin, CK14 and laminin-5γ2 observed in Western blot with the differentiation of the 
primary tumor and trans-well cell migration assay of 12 ESCC cell lines
Cell lines Differentiation Trans-well cell migration Fascin CK14 Laminin-5γ2
EC9706 well strongest high negative negative
TE12 unknown weakest negative negative negative
COLO-680N unknown strong high negative high
KYSE510 well strong high negative high
KYSE450 well strong high negative negative
KYSE410 poor strong high negative moderate
KYSE180 well strong high high moderate
KYSE150 poor weak high negative high
KYSE140 moderate weak high negative high
KYSE70 poor weak high negative moderate
KYSE30 well weak high negative negative
YES2 unknown weak high negative negativeBMC Cancer 2006, 6:296 http://www.biomedcentral.com/1471-2407/6/296
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A few previous studies have investigated the possibility of
using laminin-5γ2 chain expression as a preinvasive and
microinvasive marker [42]. In our study, positive signals
of laminin-5γ2 chain were seen in all the 3 microinvasive
lesions found occasionally (Fig 1E) and in all the 4 lesions
suspicious for invasion. The findings suggested that lam-
inin-5γ2 chain could be a microinvasive marker and
would facilitate the identification of invasive lesions that
are difficult or impossible to identify on routinely stained
histological sections.
The cell lines with high and moderate expression of lam-
inin-5γ2 displayed stronger migration phenotypes in
trans-well test than those with negative expression of lam-
inin-5γ2 [15]. These suggested that laminin-5γ2 might
play an important role in the progression of ESCC.
Matricellular proteins comprise a nonhomologous group
of extracellular regulatory macromolecules that mediate
cell-matrix interactions, but may not contribute signifi-
cantly to extracellular matrix structure. Therefore, the
matricellular proteins are different from the traditional
extracellular matrix proteins including laminin, all of
which are adhesive proteins and contribute to the struc-
tural stability of the extracellular matrix.
SPARC (secreted protein, acidic and rich in cysteine) is a
prototype of the nonstructural matricellular proteins.
Increasing evidence in the literature have suggested that
overexpression of SPARC might play a role in many types
of tumor, and both tumor and stromal cells within tumor
have been shown to express SPARC [46,47]. In the current
study, cytoplasmic SPARC in cancer cells was seen in a few
cases, and in these cases, immunoactivity was detected in
cancer cells mainly localized at the tumor-stroma inter-
face, similar to the pattern of laminin-5γ2. In contrast to
cancer cells, stromal fibroblasts were frequently and
strongly reactive for SPARC. So it could be seen in most
ESCC that SPARC was prominently expressed by stromal
fibroblasts in a background of negative cancer cell reactiv-
ity. Moreover, the immunoactivity of stromal fibroblasts
was higher in late stage ESCC than relatively early stage
ones. However, SPARC was negative in most normal
mucosa and precursor lesions. Thus, its dysregulation
might be a "late" step of carcinogenesis.
Conclusion
In summary, we have examined 10 proteins encompass-
ing a variety of functional classes in ESCC and its precur-
sor lesions using a TMA-based approach. We
distinguished the different protein expression patterns
among "early", "intermediate" and "late" progression,
which would hopefully lead to rational early-detection
strategies and prognosis strategies in patients at risk of
developing esophageal cancer, as well as of advancing.
Thereby, the proteins that displayed specific changes in
ESCC and its precursor lesions could be used as markers
to guide rational "individual" treatment.
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